Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial-Reference-Cited by-同舟云学术

Targeted‐dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial

Published:2020-09-28 Issue:5 Volume:38 Page:773-781
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Esteves Iracema¹²^ORCID,Santos Fabio Pires Souza¹,Ribeiro Andreza Alice Feitosa¹,Seber Adriana³,Sugawara Eduardo Kinio⁴,Sobrinho Jairo José do Nascimento¹,Barros José Carlos⁵,Oliveira José Salvador Rodrigues²,Fernandes Juliana Folloni¹⁶,Hamerschlak Nelson¹,Andersson Borje S.⁷,de Lima Marcos⁸,Kerbauy Fabio Rodrigues²

Affiliation:

1. Hospital Israelita Albert Einstein São Paulo Brazil

2. Universidade Federal de São Paulo (UNIFESP) São Paulo Brazil

3. Hospital Samaritano São Paulo Brazil

4. Associação Fundo de Incentivo à Pesquisa (AFIP) São Paulo Brazil

5. Transplantation Hospital Dr. Euryclides de Jesus Zerbini São Paulo Brazil

6. Bone Marrow Transplantation Unit Itaci Hospital, Faculdade de Medicina da Universidade de São Paulo (FMUSP) São Paulo Brazil

7. Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center Houston Texas USA

8. Case Western Reserve University, University Hospitals of Cleveland Cleveland Ohio USA

Funder

Ministério da Saúde

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2789

Reference38 articles.

1. A risk score for mortality after allogeneic hematopoietic cell transplantation;Parimon T;Ann Intern Med,2006

2. Toxic Injury to Hepatic Sinusoids: Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease)

3. Avoiding hepatic veno-occlusive disease: what do we know and where are we going?

4. Risk factors for hepatic veno‐occlusive disease after high‐dose busulfan‐containing regimens followed by autologous bone marrow transplantation: a study in 136 children;Méresse V;Bone Marrow Transplant,1992

5. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation;Blood Advances;2023-09-13

2. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan;Annals of Hematology;2023-04-13

3. Evaluation of different pharmacokinetically guided IV busulfan exposure ranges on adult patient outcomes after hematopoietic stem cell transplantation;Annals of Hematology;2022-12-03

4. Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation;Bone Marrow Transplantation;2022-03-31

5. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: Diagnosis, incidence, prophylaxis, and treatment;Transfusion and Apheresis Science;2022-02